Belatacept and mediastinal histoplasmosis in a kidney transplant patient

• Published in: Journal of nephropathology Vol. 5; no. 2; pp. 84 - 87
• Main Authors: Trimarchi, Hernán, Rengel, Tatiana, Andrews, José, Paulero, Matías, Iotti, Alejandro, astiero, Agustina, Lombi, Fernando, Pomeranz, Vanesa, rester, Mariano, Iriarte, Romina, Agorio, Iris
• Format: Report
• Language: English
• Published: 01.04.2016
• ISSN: 2251-8363
• DOI: 10.15171/jnp.2016.15

BACKGROUNDIn transplantation immunosuppression enhances the appearance of opportunist infections. An ideal balance between the prevention of rejection, the lowest risk of infections and the highest rates of graft survival is a continuous challenge. Lower doses of immunosuppression may diminish the risk of infections, metabolic and hemodynamic complications or even of malignancy, but may expose patients to episodes of acute rejection. New drugs are being developed to improve graft survival at the lowest risk of side effects. Belatacept has recently been introduced in kidney transplantation to inhibit the co-ligand signal of T cell stimulation. It is a drug with a safe profile, is well-tolerated and appears to improve long-term survival of kidney grafts. However, there may be an increase in opportunistic infections which may be facilitated by T cell depression, as Aspergillus sp., Cryptococcus neoformans or tuberculosis. CASE PRESENTATIONWe describe a 59-year-old female who developed fever, clinical wasting and a mediastinal mass 31 months after receiving a living non-related kidney transplant while on belatacept therapy. A mediastinal node biopsy disclosed the presence of Histoplasma capsulatum. Infection successfully resolved after appropriate antifungal treatment. CONCLUSIONSTo our knowledge, this is the first reported case of Histoplasma capsulatum in a kidney transplanted patient on belatacept therapy.